ArticleInvestigational new drugs2015

BYL719, a selective inhibitor of phosphoinositide 3-Kinase α, enhances the effect of selumetinib (AZD6244, ARRY-142886) in KRAS-mutant non-small cell lung cancer.

Bo Mi Ku et al.PubMed ↗Publisher ↗

No numbers read from the abstract.